Perspective: Multimodality Radionuclide Therapy of Progressive Disseminated Lymphoma and Neuroendocrine Tumors as a Paradigm for Cancer Control

Abstract

Get full access to this article

View all access options for this article.

References

Gilles

. Radiologic reviews: More second guessing from armchairs cannot lead the way. J Clin Oncol, 2011; 30:116.

Booth

, Eisenhauer

. Progression-free survival: Meaningful or simply measurable? J Clin Oncol, 2012; 30:1030.

McLaughlin

, Grillo-Lopez

, Link

et al. Rituximab chimeric anti-CD 20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol, 1998; 16:2825.

Hiddemann

, Kneba

, Dreyling

et al. Frontline therapy with rituximab added to the combination of cylcophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German low-grade lymphoma study group. Blood, 2005; 106:3725.

Skvortsova

, Popper

, Skvortsov

et al. Pre-treatment with rituximab enhances radiosensitivity of non-Hodgkin's lymphoma cells. J Radiat Res (Tokyo), 2005; 46:241.

Leahy

, Turner

. Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with ¹³¹I-ritixumab in routine clinical practice: 10 year single institution experience of 142 consecutive patients. Blood, 2011; 117:45.

McQuillan

, Macdonald

WBG

, Leahy

et al. First-line radioimmunotherapy of newly diagnosed, advanced follicular non-Hodgkin lymphoma with ¹³¹I-rituximab: The INITIAL study. 2011 ASH Annual Scientific MeetingAbstract 3719.

Illidge

, Bayne

, Brown

. Phase 1/2 study of fractionated ¹³¹I-rituximab in low-grade B-cell lymphoma: The effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. Blood, 2009; 113:1412.

Shen

, Forero

, Meredith

et al. Impact of rituximab treatment on ⁹⁰Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma. J Nucl Med, 2010; 51:150.

10.

Press

, Unger

, Rimza

. A Phase III randomized intergroup trial (SWOG S0016) of CHOP chemotherapy plus rituximab vs CHOP chemotherapy plus Iodine-131 tositumomab for the treatment of newly diagnosed follicular non-Hodgkin's lymphoma. 2011 ASH Annual Scientific MeetingAbstract 98San Diego.

11.

Fowler

, Neelapu

, Fanale

et al. Phase II study with R-FND followed by ⁹⁰Y ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance for untreated high-risk follicular lymphoma. 2011 ASH Annual Scientific MeetingAbstract 99San Diego.

12.

Morschhauser

, Radford

, Van Hoof

et al. Phase III trial of consolidation therapy with Yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol, 2008; 26:5156.

13.

Cheson

. Time to remember to forget dose-intensification in lymphoma. J Clin Oncol, 2011; 37:3954.

14.

Shimoni

, Avivi

, Rowe

et al. A randomised study comparing Yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. Cancer, 2012[Epub ahead of print]10.1002/cncr27418.

15.

Vose

, Carter

, Burns

et al.

Randomized Phase III Trial of ¹³¹iodine-tositumomab (Bexxar)/carmustine, etoposide, cytarabine, melphalan (BEAM) Vs. rituximab/BEAM and autologous stem cell transplantation for relapsed diffuse large B-cell lymphoma (DLBCL): No difference in progression-free (PFS) or overall survival (OS)

ASH Annual Scientific Meeting 2011Abstract 661San Diego.

16.

Kruger

, Cooney

, Turner

. Iodine-131 rituximab radioimmunotherapy with BEAM conditioning and autologous stem cell transplant salvage therapy for relapsed/refractory aggressive non-Hodgkin lymphoma. Cancer Biother Radiopharm.

17.

Kwekkeboom

, de Herder

, Kam

et al. Treatment with the radiolabeled somatostatin analog [^l77Lu-DOTA⁰, Tyr ³] octreotate: Toxicity, efficacy and survival. J Clin Oncol, 2008; 26:2124.

18.

van Essen

, Krenning

, Kam

et al. Report on short-term side effects of treatments with ¹⁷⁷Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging, 2008; 35:743.

19.

Claringbold

, Brayshaw

, Price

et al. Phase II study of radiopeptide ¹⁷⁷Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. Eur J Nucl Med Mol Imaging, 2011; 38:302.

20.

Strosberg

, Fine

, Choi

et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer, 2011; 117:268.

21.

Claringbold

, Price

, Turner

. Phase I-II study of radiopeptide ¹⁷⁷Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors. Cancer Biother Radiopharm, 2012.

22.

Falconi

, Bartsch

, Eriksson

. ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: Well-differentiated pancreatic non-functioning tumors. Neuroendocrinology, 2012; 95:120.

23.

Bousquet

, Lasfargues

, Chalabi

et al. Current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy. J Clin Endocrinol Metab, 2012; 97:727.

24.

Yao

, Shah

, Ito

et al. RAD001 in advanced neuroendocrine tumors, third trial (RADIANT-3) study group. N Engl J Med, 2011; 364:514.

25.

Trimble

, Abrams

, Meyer

. Improving cancer outcomes through international collaboration in academic cancer treatment trials. J Clin Oncol, 2009; 27:5109.

26.

Hearn

, Sullivan

. The impact of the ‘clinical trials' directive on the cost and conduct of non-commercial cancer trials in the UK. Eur J Cancer, 2007; 43:8.

27.

Kulke

, Siu

, Tepper

. Future directions in the treatment of neuroendocrine tumors: Consensus report of the National Cancer Institute neuroendocrine tumor clinical trials planning meeting. J Clin Oncol, 2011; 29:934.

28.

ENETS 2011 consensus guidelines for the management of patients with digestive neuroendocrine tumors. Neuroendocrinology, 2012; 95:67.

29.

Rinke

, Müller

, Schade-Brittinger

et al. Placebo-controlled double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumour growth in patients with metastatic neuroendocrine midgut tumours: A report from the PROMID Study Group. J Clin Oncol, 2009; 27:4656.

30.

Delbaldo

, Faivre

, Dreyer

et al. Sunitinib in advanced pancreatic neuroendocrine tumors: Latest evidence and clinical potential. Ther Adv Med Oncol, 2012; 4:9.

31.

Turner

. Outpatient therapeutic nuclear oncology. Ann Nucl Med, 2012; 26:289.

32.

Brans

, Van Den Eynde

, Audenaert

et al. Depression and anxiety during isolation and radionuclide therapy. Nucl Med Commun, 2003; 24:881.

33.

Calais

, Tuner

. Outpatient Iodine-131 rituximab radioimmunotherapy of non-Hodgkin lymphoma: A study in safety. Clin Nucl Med, 2012; 37:732.

34.

Lo Russo

, Schnipper

, Stewart

et al. Translating clinical trials into meaningful outcomes. Clin Cancer Res, 2010; 16:5951.

35.

Fleming

. Issues in using progression-free survival when evaluating oncology products. J Clin Oncol, 2009; 27:2874.

36.

Baker

. Biomarkers, subgroup evaluation, and clinical trial design. Discov Med, 2012; 13:187.

37.

Longo

. Tumor heterogeneity and personalised medicine. N Engl J Med, 2012; 366:956.

38.

Stewart

, Whitney

, Kurzrock

. Equipoise lost: Ethics, costs, and the regulation of cancer clinical research. J Clin Oncol, 2010; 28:2925.